报价延迟最少15分钟:2026/04/21 23:58 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.84 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-129.10/-187.84
|
|
企业价值
3.13M
|
| 资产负债 |
|
每股账面净值
11.07
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
838.14K
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus;and Tripledemic. |
